Valganciclovir

Kathryn Dzintars, Pharm.D., BCPS, Paul G. Auwaerter, M.D.

INDICATIONS

FDA

  • Treatment of CMV retinitis (AIDS).
  • Prevention of CMV disease: renal, cardiac and kidney-pancreas transplant patients at high risk for CMV disease (e.g., donor positive, recipient negative).
    • Not indicated in liver transplant patients.
  • Prevention of CMV disease in renal and cardiac transplant patients at high risk, pediatric.

NON-FDA APPROVED USES

  • Prevention of disseminated CMV disease of the contralateral eye in patients treated with intraocular ganciclovir implant (no longer manufactured).

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: July 16, 2023